2810747-78-3
2810747-78-3
Chemical Structure
BLU0588
- CAS No.: 2810747-78-3
- Formula:C26H25N5O
- Molecular Weight:423.51
InChIKey: YXSWSKFLTNJZEO-DNQXCXABSA-N
SMILES: O=C(C1=CN=C(C2=C3C(NC=C3)=NC=C2)C=C1)N[C@H]4[C@H](N5CCCC5)CC6=CC=CC=C64
Biological Activity: BLU0588 is an orally active, potent and selective PRKACA (protein kinase cAMP-activated catalytic subunit alpha) kinase inhibitor, with an IC50 of 1 nM and dissociation constant (Kd) of 4 nM. BLU0588 can be used for fibrolamellar carcinoma (FLC) research[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
BLU0588 | 97.63% | BLU0588 is an orally active, potent and selective PRKACA (protein kinase cAMP-activated catalytic subunit alpha) kinase inhibitor, with an IC50 of 1 nM and dissociation constant (Kd) of 4 nM. BLU0588 can be used for fibrolamellar carcinoma (FLC) research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
GW788388 | 99.92% | GW788388 is a potent and selective inhibitor of ALK5 with IC50 of 18 nM, and also inhibits TGF-β type II receptor and activin type II receptor activities, without inhibiting BMP type II receptor. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
OXA-06 hydrochloride | 99.89% | OXA-06 hydrochloride is an ATP-competitive ROCK inhibitor that blocks anchorage-dependent growth and invasion of non-small cell lung cancer cell lines. OXA-06 hydrochloride inhibits cofilin phosphorylation but does not stimulate apoptosis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
OXA-06 | OXA-06 is a pharmacologic inhibitor of ROCK, possessing antitumor activity by impairing cell migration and MYPT1 phosphorylation in PANC-1 cells. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
LASSBio-1829 hydrochloride | LASSBio-1829 hydrochloride is an orally active IKK2 inhibitor with an IC50 of 3.8 μM against the human target (Sf21 cells). LASSBio-1829 hydrochloride blocks signal transduction of the inflammation-associated NF-κB activation pathway. LASSBio-1829 hydrochloride reduces leukocyte migration, TNF-α biosynthesis, ROS production and NO production. LASSBio-1829 hydrochloride exhibits anti-inflammatory activity in a carrageenan-induced subcutaneous air pouch mouse model. LASSBio-1829 hydrochloride alleviates licking behavior during the inflammatory phase of the mouse formalin test. LASSBio-1829 hydrochloride can be used in inflammation-related research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
PKCiota-IN-1 | PKCiota-IN-1 (compound 51) is a potent PKCiota (PKC-ι) inhibitor with an IC50 of 2.7 nM. PKCiota-IN-1 also inhibits PKC-α and PKC-ε with IC50s of 45 nM and 450 nM, respectively. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
PKCiota-IN-2 | PKCiota-IN-2 (Compound 49) is a potent PKCiota (PKC-ι) inhibitor with an IC50 of 2.8 nM. PKCiota-IN-2 also inhibits PKC-α and PKC-ε with IC50s of 71 nM and 350 nM, respectively. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
sEH-IN-12 | sEH-IN-12 is a potent soluble epoxide hydrolase (sEH) inhibitor with the property of inhibiting sEH activity. sEH-IN-12 was successfully used in the construction and selection of small molecule libraries, showing excellent biological activity. The development of sEH-IN-12 provides a new tool for drug discovery targeting sEH. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Niravoline | Niravoline (RU51599) is an arginine vasopressin (AVP) release inhibitor and a selective kappa opioid receptor agonist. Niravoline has a pure water diuresis effect without associated electrolyte excretion. Niravoline can reduce brain oedema following transient forebrain ischaemia in rats. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
BLU2864 | 99.50% | BLU2864 is an orally active, highly selective, ATP-competitive PRKACA inhibitor (IC50=0.3 nM). BLU2864 shows anti-tumor activity. BLU2864 can be used in cancer and polycystic kidney disease research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
GSK 650394 | 99.76% | GSK 650394 is a novel SGK inhibitor with IC50 of 62 nM and 103 nM for SGK1 and SGK2 in the SPA assay respectively. GSK 650394 also inhibits influenza virus replication. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
